What is Regor Therapeutics?
Founded in 2018 and headquartered in Boston, Massachusetts, Regor Therapeutics operates at the intersection of advanced biotechnology and clinical medicine. The company is dedicated to the discovery and development of novel therapeutics targeting oncology, metabolic diseases, and autoimmune conditions. By leveraging a sophisticated research engine, Regor aims to address significant unmet medical needs, positioning itself as a high-growth entity within the competitive life sciences landscape. Its operational model focuses on translating complex biological insights into scalable therapeutic solutions, attracting substantial interest from institutional backers focused on long-term healthcare innovation.
How much funding has Regor Therapeutics raised?
Regor Therapeutics has raised a total of $90M across 1 funding round:
Series B
$90M
Series B (2021): $90M with participation from Vertex Ventures China, Lilly Asia Ventures, Lanting Capital, TF Capital, and Loyal Valley Capital
Key Investors in Regor Therapeutics
Lilly Asia Ventures
Lilly Asia Ventures is a premier biomedical venture capital firm that partners with entrepreneurs to build companies developing breakthrough products for human health.
TF Capital
TF Capital is a specialized investment firm focused on the healthcare and life sciences sectors, providing strategic support to early and growth-stage companies.
Loyal Valley Capital
Loyal Valley Capital is a private equity firm that invests in high-growth companies, leveraging deep industry expertise to drive long-term value creation.
What's next for Regor Therapeutics?
With the recent infusion of capital, Regor Therapeutics is well-positioned to transition from early-stage research into more advanced clinical development phases. The strategic roadmap likely involves expanding its internal R&D capabilities and accelerating the progression of its lead candidates through regulatory milestones. As the company scales, the focus will remain on optimizing its therapeutic platform to maintain a competitive edge in the oncology and metabolic disease markets. Continued collaboration with its syndicate of venture capital partners will be instrumental in navigating the complexities of drug commercialization and securing future market share in the global biopharmaceutical industry.
See full Regor Therapeutics company page
